Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
暂无分享,去创建一个
E. Sausville | M. Edelman | E. Heath | P. LoRusso | R. Messmann | M. Pilat | Patricia M Lorusso | Martin J Edelman | Susan L Bever | Karen M Forman | Maryjo Pilat | Mary F Quinn | Jing Li | Elisabeth I Heath | Lisa M Malburg | Patrick J Klein | Christopher P Leamon | Richard A Messmann | Edward A Sausville | C. Leamon | Jing Li | P. Klein | L. Malburg | M. Quinn | K. Forman | S. Bever
[1] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[2] E. Sausville,et al. Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐Vinca Alkaloid Conjugate EC145 in Cancer Patients , 2009, Journal of clinical pharmacology.
[3] P. Low,et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.
[4] Barry A. Siegel,et al. Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor–Positive Solid Tumors , 2008, Journal of Nuclear Medicine.
[5] A. Rossi,et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. , 2003, Anticancer research.
[6] R. Advani,et al. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies , 2011, Clinical Cancer Research.
[7] V. Roche. Cancer and chemotherapy , 2008 .
[8] P. Low,et al. Ligand Binding and Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery , 2004, Molecular Pharmacology.
[9] P. Low,et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. , 2009, Human pathology.
[10] L. Cervenak,et al. Caveolae--an alternative endocytotic pathway for targeted drug delivery. , 2004, Critical reviews in therapeutic drug carrier systems.
[11] M. Sliwkowski,et al. Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.
[12] J. Reddy,et al. Comparative preclinical activity of the folate‐targeted Vinca alkaloid conjugates EC140 and EC145 , 2007, International journal of cancer.
[13] R. Burger,et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Reddy,et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. , 2007, Cancer research.
[15] Y. Maitani,et al. Selective delivery of folate–PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft: Effect of chain length and amount of folate–PEG linker , 2008 .
[16] Rasmus Niemi,et al. Targeting of porous hybrid silica nanoparticles to cancer cells. , 2009, ACS nano.
[17] J. Reddy,et al. Folate receptor specific anti-tumor activity of folate–mitomycin conjugates , 2006, Cancer Chemotherapy and Pharmacology.
[18] H. Santhapuram,et al. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. , 2006, Bioorganic & medicinal chemistry letters.
[19] P. Canal,et al. Toxicity Patterns of Cytotoxic Drugs , 2003, Investigational New Drugs.
[20] E. Sausville,et al. Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications , 2011, Journal of Pharmacology and Experimental Therapeutics.
[21] K. Yoshikawa,et al. Spontaneous Generation of Giant Liposomes from an Oil/Water Interface , 2007, Chembiochem : a European journal of chemical biology.